Jeff Leiden, Vertex Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about his company's cystic fibrosis drugs and the future for biotech and pharma under the current administration.
White House officials met with executives from drug companies as well as academic and government health leaders.
CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The "Fast Money" traders weigh in on trading the pharma and biotech space.
CNBC's Meg Tirrell reports Vertex Pharmaceuticals' quarterly earnings.
Jim Cramer finds that the S&P 500's best-performing stocks are poised to overshoot a market decline.
Some of the names on the move ahead of the open.
These are the stocks posting the largest moves after the bell.
Drugs, travel, jewelry and social media in the blitz
Jim Cramer reviews the stocks of the S&P 500 to find out if they could run out of fuel in the new year.
Michael Yee, RBC Capital Markets, and Michael King, JMP Securities, look back at a very rough year for biotech stocks and discuss whether the sector is primed to take off.
In the likely repeal of the Affordable Care Act, these health-care stocks should perform well, according to some analysts.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
The company said at a conference that Orkambi refills have lagged during the third quarter.
The biotechnology sector made sizeable gains on Monday amid acquisition news.
After Pfizer's $14 billion proposed acquisition of Medivation, these biotech stocks could emerge as winners, if history is any guide.
CNBC's Meg Tirrell reports on the action in the IBB biotech ETF after Pfizer announced it was buying Medivation and what some other big M&A deals could be coming down the line. The "Fast Money" traders weigh in.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
The hunt for yield has increased valuations for pharma stocks above their biotech counterparts, a rare feat that may present a buying opportunity.
Check out the companies making headlines after the bell on Monday.
In a world mired in sluggish growth, those looking to buy attractively valued growth stocks may need to get creative. Asset manager Jason Donville has some ideas.